Parameter | Total evaluations (%) | Evaluations in VAP group (%) |
---|---|---|
Number of evaluations | 219 (100%) | 38 (100%) |
Tracheostomy (n [%]) | 59 (26.9%) | 10 (26.3%) |
Atelectasisa (n [%]) | 13 (6.0%) | 6 (15.7%) |
Lung edemaa (n [%]) | 35 (16.0%) | 9 (23.6%) |
Lung contusiona (n [%]) | 6 (2.7%) | 1 (2.6%) |
Pleural effusiona (n [%]) | 21 (9,5%) | 8 (21.0%) |
Previous lung disease (n [%]) | 30 (13.6%) | 6 (15.7%) |
COPD | 16 (7.3%) | 3 (7.8%) |
Cancer | 11 (5.0%) | 2 (5.2%) |
Asthma | 2 (0.9%) | 1 (2.6%) |
Pulmonary fibrosis | 1 (0.4%) | None |
Broncoaspiration (n [%]) | 12 (5.4%) | 3 (7.8%) |
Sepsis (n [%]) | 46 (21.0%) | 14 (36.8%) |
ARDS (n [%]) | 12 (5,4%) | 3 (7.8%) |
Renal failure (n [%]; creatinine >2.0 mg/dl) | 91 (41.5%) | 20 (52.6%) |
Diabetes (n [%]) | 35 (16.0%) | 5 (13.1%) |
Chemotherapy (n [%]) | 13 (6.0%) | 2 (5.2%) |
Radiotherapy (n [%]) | 2 (0.9%) | None |
Immunossupressants drugs (n [%]) | 5 (2.2%) | 1 (2.6%) |
AIDS (n [%]) | 3 (1.3%) | None |
Renal transplantation (n [%]) | 5 (2.2%) | 1 (2.6%) |
Abdominal surgery (n [%]) | 32 (14.6%) | 7 (18.4%) |
Multiple trauma (n [%]) | 21 (9.5%) | 3 (7.9%) |
Neuromuscular blocking agents (n [%]) | 7 (3.1%) | 7 (18.4%) |
Central venous line (n [%]) | 215 (98.0%) | 38 (100%) |
Intracranial pressure monitoring (n [%]) | 20 (9.1%) | 1 (2.6%) |